Carpenter Valerie J, Saleh Tareq, Gewirtz David A
Department of Pharmacology and Toxicology and Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Massey Cancer Center, Richmond, VA 23298, USA.
Cancers (Basel). 2021 Feb 10;13(4):723. doi: 10.3390/cancers13040723.
Senolytics represent a group of mechanistically diverse drugs that can eliminate senescent cells, both in tumors and in several aging-related pathologies. Consequently, senolytic use has been proposed as a potential adjuvant approach to improve the response to senescence-inducing conventional and targeted cancer therapies. Despite the unequivocal promise of senolytics, issues of universality, selectivity, resistance, and toxicity remain to be further clarified. In this review, we attempt to summarize and analyze the current preclinical literature involving the use of senolytics in senescent tumor cell models, and to propose tenable solutions and future directions to improve the understanding and use of this novel class of drugs.
衰老细胞裂解剂是一类作用机制多样的药物，可清除肿瘤及多种与衰老相关病理状态下的衰老细胞。因此，有人提出使用衰老细胞裂解剂作为一种潜在的辅助方法，以提高对诱导衰老的传统和靶向癌症疗法的反应。尽管衰老细胞裂解剂有着明确的前景，但通用性、选择性、耐药性和毒性等问题仍有待进一步阐明。在这篇综述中，我们试图总结和分析目前涉及在衰老肿瘤细胞模型中使用衰老细胞裂解剂的临床前文献，并提出合理的解决方案和未来方向，以增进对这类新型药物的理解和应用。
